Open access · OA
via OpenAlex
Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome
Cristina Bozzao, Patrizia Lastella, Maurizio Ponz de Leòn, Monica Pedroni, Carmela Di Gregorio, Francesco Domenico D'Ovidio, Nicoletta Resta, Fernando Prete, Ginevra Guanti, Alessandro Stella
Cancer · 2011 · ▲ 15 citations
Abstract
BACKGROUND: In patients with Lynch syndrome, germline mutations in DNA mismatch repair (MMR) genes cause a high risk of developing a broad spectrum of cancers. To date, the management of patients with Lynch syndrome has represented a major challenge because of large variations in age at cancer onset. Several factors, including genetic anticipation, have been proposed to explain this phenotypic heterogeneity, but the molecular mechanisms remain unknown. Telomere(definition) shortening is a common event in tumorigenesis and also has been observed in different familial cancers. In this study, the authors investigated the possibility of a relation between telomere length and cancer onset in patients with Lynch syndrome. METHODS: The mean telomere length was measured using quantitative polymerase chain reaction in peripheral blood samples from a control group of 50 individuals, from 31 unaffected mutation carriers, and from 43 affected patients, and the results were correlated with both gene mutation and cancer occurrence. In affected patients, telomere attrition was correlated with age at cancer onset. In all patients, a t test was used to assess the linearity of the regression. RESULTS: A significant correlation between telomere length and age was observed in both affected and unaffected mutation carriers (P = .0016 and P = .004, respectively) and in mutS homolog 2 (MSH2) mutation carriers (P = .0002) but not in mutL homolog 1 (MLH1) mutation carriers. Telomere attrition was correlated significantly with age at onset in MSH2 carriers (P = .004), whereas an opposite trend toward longer telomeres in patients with delayed onset was observed in MLH1 carriers. CONCLUSIONS: The current data suggested that telomere dynamics differ between MLH1 and MSH2 mutation carriers. It is possible that subtle, gene-specific mechanisms can be linked to cancer onset and anticipation in patients with Lynch syndrome.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/cncr.26022
- Canonical
- link ↗
- Fetched
- 2026-06-02 MST
Cite this
APA
Bozzao, C., Lastella, P., Leòn, M.P.D., Pedroni, M., Gregorio, C.D., D'Ovidio, F.D., Resta, N., Prete, F., Guanti, G., & Stella, A. (2011). Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. <em>Cancer</em>. https://doi.org/10.1002/cncr.26022
Vancouver
Bozzao C, Lastella P, Leòn MPD, Pedroni M, Gregorio CD, D'Ovidio FD, et al. Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. Cancer. 2011. doi:10.1002/cncr.26022.
BibTeX
@article{cristina2011Analys,
title = {Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome},
author = {Cristina Bozzao and Patrizia Lastella and Maurizio Ponz de Leòn and Monica Pedroni and Carmela Di Gregorio and Francesco Domenico D'Ovidio and Nicoletta Resta and Fernando Prete and Ginevra Guanti and Alessandro Stella},
journal = {Cancer},
year = {2011},
doi = {10.1002/cncr.26022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
PLoS ONE 2013
Open access · CC-BY
Telomere Length and Genetic Anticipation in Lynch Syndrome
Cancer Research 2007
Open access · OA
Younger Age of Cancer Initiation Is Associated with Shorter Telomere Length in Li-Fraumeni Syndrome
Journal of Clinical Medicine 2020
Open access · CC-BY
Increased Sensitivity of PBMCs Isolated from Patients with Rheumatoid Arthritis to DNA Damaging Agents Is Connected with Inefficient DNA Repair
The Journal of Clinical Endocrinology & Metabolism 2014
Open access · OA
Quantitative Analysis of Methylation Defects and Correlation With Clinical Characteristics in Patients With Pseudohypoparathyroidism Type I and GNAS Epigenetic Alterations
Expert Opinion on Pharmacotherapy 2021
Preprint · OA
Development of the PARP inhibitor talazoparib for the treatment of advanced<i>BRCA1</i>and<i>BRCA2</i>mutated breast cancer
Blood 2020
Open access · OA